news
75 percent of nanopharmaceuticals are being developed for oncology
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
List view / Grid view
Seattle Genetics
news
FDA Breakthrough Therapy granted to bladder cancer treatment
FDA Breakthrough Therapy Designation has been granted to PADCEV™ in combination with pembrolizumab in first-line advanced bladder cancer.
news
Takeda and Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma
1 August 2016 | By Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.
Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement...
news
Five-year data from Phase II trial of Adcetris published
19 July 2016 | By Victoria White, Digital Content Producer
The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma...
news
Trial of Adcetris and Opdivo in non-Hodgkin lymophoma starts
23 December 2015 | By Victoria White
The phase 1/2 clinical trial will evaluate Adcetris (brentuximab vedotin) in combination with Opdivo (nivolumab) in patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas...
news
Phase 3 trial of Adcetris in Hodgkin lymphoma completes target enrolment
27 October 2015 | By Victoria White
Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission...
